Epstein-Barr Virus (EBV) Antibodies to Viral Capsid Antigen (VCA), IgG

The Epstein-Barr Virus (EBV) Antibodies to Viral Capsid Antigen (VCA), IgG test is used in the differential diagnosis of infectious mononucleosis and for serologic staging of EBV infection. VCA IgG develops early in primary infection and persists for life; interpreted together with VCA IgM, EA IgG, and EBNA IgG, it contributes to an antibody profile that helps categorize acute primary, past (latent), or reactivated EBV infection. This assay supports laboratory confirmation in patients with suspected infectious mononucleosis, assists in evaluating chronic or persistent EBV serologic patterns, and may aid in assessing the etiologic role of EBV in select lymphoproliferative and EBV-associated malignancies when used alongside appropriate adjunctive tests. Common synonyms include EBV Ab VCA, IgG and EBV-VCA Antibodies, IgG.

Epstein-Barr virus (EBV) is a gammaherpesvirus (subfamily Gammaherpesvirinae) that targets upper respiratory and gastrointestinal epithelium and B lymphocytes. During its replicative cycle, EBV expresses distinct antigen groups—early antigen (EA), viral capsid antigen (VCA), membrane antigen (MA), and Epstein-Barr nuclear antigens (EBNA)—which elicit antibody responses in a characteristic temporal sequence. Transmission occurs primarily via saliva. Primary infection in immunocompetent individuals is frequently asymptomatic, but may manifest as infectious mononucleosis. The virus establishes lifelong latency in B cells with potential for reactivation. EBV is associated with conditions that include infectious mononucleosis, Burkitt lymphoma, and nasopharyngeal carcinoma. VCA IgG usually becomes detectable within 1–4 weeks of symptom onset, peaks by about two months, and persists for life. Persistently high titers can be seen in chronic or reactivated infection. A negative VCA IgG result early in the course of illness does not exclude acute EBV infection. IgG avidity reflects maturation of the humoral response: low-avidity VCA IgG supports recent primary infection, and avidity increases over subsequent weeks to months, becoming high in past infection. Results require integration with clinical findings and other EBV serologies; the assay is qualitative, and the magnitude of a positive numeric signal above the cutoff does not quantify antibody concentration.